TARSUS

📅 Upcoming

🕒 Recent(90d)

News

• Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
  After former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its nex…
  fiercebiotech · 3d ago
• Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M
  Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.”
  biopharma_dive · 1mo ago
• Tarsus bets $450M on Alkeus’ Stargardt drug
  To broaden its ophthalmology portfolio, Tarsus Pharmaceuticals is dishing out $450 million upfront to acquire Phase 3 biotech Alkeus Pharmaceuticals, the companies said Thursday morning. It's the l…
  endpoints · 1mo ago
• Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug
  Tarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals for its phase 3-stage retinal disease therapy that's being touted as a potential blockbuster.
  fiercebiotech · 1mo ago
• ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
  The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
  biopharma_dive · 2mo ago
• Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront
  Plus news on Alchemab, Scipher and Forte. 💉 Ipsen’s Dysport aces Phase 3 migraine trials: The biotech’s injectable neurotoxin met the primary endpoint of reducing monthly migraine days in two ...
  endpoints · 2mo ago